Relapsed/Refractory Archives

May 25, 2023

ASH 2022: Dr. Richard Furman on Acalabrutinib for Treatment of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

Follow-up results from a phase 1/2 trial of acalabrutinib in CLL/SLL patients further confirm that acalabrutinib is safe & effective.

May 25, 2023

ASH 2022: Dr. Bill Wierda on Pharmacological Profiling of Cells from Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Pirtobrutinib

Pirtobrutinib can extend the benefits of Bruton tyrosine kinase (BTKi) in patients with CLL/SLL who are resistant to covalent BTKi

May 2, 2023

ASH 2022: Dr. Mazyar Shadman on Enitociclib, a CDK9 Inhibitor, for Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

We discuss enitociclib, an experimental CDK9 inhibitor in development for treating NHL and CLL.

May 2, 2023

ASH 2022: Dr. Farrukh Awan on Real-World Treatment Patterns Among Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) who Have Received 2+ Lines of Therapy

A study that used real-world data to see what treatments are being given to patients with CLL/SLL who have received 2+ lines of therapy

April 26, 2023

ASH 2022: Dr. Neil Kay on Combination Therapies for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

We discuss combination therapies for CLL and SLL, focusing on the combination of ibrutinib plus venetoclax.

April 10, 2023

ASH 2022: Dr. Arnon Kater on Subcutaneous Epcoritamab for Richter’s Syndrome

Early results from a phase 1b/2 trial show that epcoritamab has a manageable safety profile and an encouraging response rate in patients with Richter syndrome.

April 10, 2023

ASH 2022: Dr. Arnon Kater on Long-Term Immune Changes After Treatment with Venetoclax Plus Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Study shows that patients with relapsed/refractory CLL recovered immune function after fixed-duration treatment with venetoclax + rituximab.

April 10, 2023

ASH 2022: Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study

The noncovalent BTK inhibitor nemtabrutinib shows promising antitumor activity and a manageable safety profile in highly relapsed/refractory patients with chronic lymphocytic leukemia CLL/SLL.

March 24, 2023

ASH 2022: Dr. Neil Kay on Senescence in CAR-T Cells

This research shows that senescence (biological aging) can occur in CAR-T cells, reducing their ability to kill cancer cells.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Relapsed/Refractory

ASH 2022: Dr. Richard Furman on Acalabrutinib for Treatment of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

ASH 2022: Dr. Bill Wierda on Pharmacological Profiling of Cells from Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Pirtobrutinib

ASH 2022: Dr. Mazyar Shadman on Enitociclib, a CDK9 Inhibitor, for Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

ASH 2022: Dr. Farrukh Awan on Real-World Treatment Patterns Among Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) who Have Received 2+ Lines of Therapy

ASH 2022: Dr. Neil Kay on Combination Therapies for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

ASH 2022: Dr. Arnon Kater on Subcutaneous Epcoritamab for Richter’s Syndrome

ASH 2022: Dr. Arnon Kater on Long-Term Immune Changes After Treatment with Venetoclax Plus Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

ASH 2022: Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study

ASH 2022: Dr. Neil Kay on Senescence in CAR-T Cells

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT US

CONTACT